The judge’s decision is a win for public health, but the back-and-forth on vaccine policy may undermine the public’s trust in science.
Articles on ACIP
Displaying all articles
In an unprecedented move, health officials cut the number of vaccines routinely recommended for children from 17 to 11.
Federal officials are questioning the safety of the vaccine series children receive. Here’s the story of how the childhood vaccine schedule came about.
The decision undoes a highly effective 34-year prevention strategy that has nearly eliminated early childhood hepatitis B infections in the U.S.
A cascade of changes to eligibility guidelines for the updated COVID-19 vaccines left Americans unsure whether they could still get the shot. That’s where off-label use comes in.
Before universal vaccination for hepatitis B began in 1991, 18,000 children contracted the virus by age 10 each year, and most of them developed chronic illness and liver damage. Vaccination reduced those infections by 95%.
The Advisory Committee on Immunization Practices guides the CDC’s hand on vaccine policy, but some of its new members have voiced anti-vaccine views.
The CDC and FDA said the benefits of the Johnson & Johnson vaccine far outweigh the low risk of developing rare blood clots and lifted a pause on the vaccine’s use. A doctor explains.
Top contributors
-
Assistant Professor of Pediatrics, University of Colorado Anschutz
-
Clinical Associate Professor of Infectious Diseases, Stanford University
-
Professor of Medicine, University of Virginia
-
Associate Professor of Development and Global Health Economics, University of Notre Dame
-
Associate Professor of Pediatrics, University of Cincinnati
-
Assistant Professor of Law and Assistant Professor of Philosophy, Washington and Lee University
-
Assistant Professor of Epidemiology and Biostatistics, University of Illinois Chicago